Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.

Détails

ID Serval
serval:BIB_E968A59CAD15
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.
Périodique
European heart journal
Auteur(s)
Li X.S., Obeid S., Klingenberg R., Gencer B., Mach F., Räber L., Windecker S., Rodondi N., Nanchen D., Muller O., Miranda M.X., Matter C.M., Wu Y., Li L., Wang Z., Alamri H.S., Gogonea V., Chung Y.M., Tang W.H., Hazen S.L., Lüscher T.F.
ISSN
1522-9645 (Electronic)
ISSN-L
0195-668X
Statut éditorial
Publié
Date de publication
14/03/2017
Peer-reviewed
Oui
Volume
38
Numéro
11
Pages
814-824
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
Systemic levels of trimethylamine N-oxide (TMAO), a pro-atherogenic and pro-thrombotic metabolite produced from gut microbiota metabolism of dietary trimethylamine (TMA)-containing nutrients such as choline or carnitine, predict incident cardiovascular event risks in stable primary and secondary prevention subjects. However, the prognostic value of TMAO in the setting of acute coronary syndromes (ACS) remains unknown.
We investigated the relationship of TMAO levels with incident cardiovascular risks among sequential patients presenting with ACS in two independent cohorts. In the Cleveland Cohort, comprised of sequential subjects (n = 530) presenting to the Emergency Department (ED) with chest pain of suspected cardiac origin, an elevated plasma TMAO level at presentation was independently associated with risk of major adverse cardiac events (MACE, including myocardial infarction, stroke, need for revascularization, or death) over the ensuing 30-day (4th quartile (Q4) adjusted odds ratio (OR) 6.30, 95% confidence interval (CI), 1.89-21.0, P < 0.01) and 6-month (Q4 adjusted OR 5.65, 95%CI, 1.91-16.7; P < 0.01) intervals. TMAO levels were also a significant predictor of the long term (7-year) mortality (Q4 adjusted HR 1.81, 95%CI, 1.04-3.15; P < 0.05). Interestingly, TMAO level at initial presentation predicted risk of incident MACE over the near-term (30 days and 6 months) even among subjects who were initially negative for troponin T (< 0.1 ng/mL) (30 days, Q4 adjusted OR 5.83, 95%CI, 1.79-19.03; P < 0.01). The prognostic value of TMAO was also assessed in an independent multicentre Swiss Cohort of ACS patients (n = 1683) who underwent coronary angiography. Trimethylamine N-oxide again predicted enhanced MACE risk (1-year) (adjusted Q4 hazard ratios: 1.57, 95% CI, 1.03-2.41; P <0.05).
Plasma TMAO levels among patients presenting with chest pain predict both near- and long-term risks of incident cardiovascular events, and may thus provide clinical utility in risk stratification among subjects presenting with suspected ACS.

Mots-clé
Acute Coronary Syndrome/drug therapy, Acute Coronary Syndrome/metabolism, Acute Coronary Syndrome/mortality, Biomarkers/metabolism, Cardiotonic Agents/therapeutic use, Case-Control Studies, Female, Gastrointestinal Microbiome/physiology, Humans, Kaplan-Meier Estimate, Male, Methylamines/metabolism, Middle Aged, Myocardial Infarction/etiology, Myocardial Infarction/mortality, Prognosis, Risk Assessment, Stroke/etiology, Stroke/mortality, Acute coronary syndrome, All-cause mortality, Choline, Gut microbiota, Incident major adverse cardiac events, Risk stratification, Trimethylamine N-oxide
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/01/2017 19:53
Dernière modification de la notice
20/08/2019 17:12
Données d'usage